# Hydroxyprogesterone caproate

## Progeston Depot inj 125mg/1mL(普寶胎)

| TAH Drug Code      | [IPROD125](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPROD125)                                                                                                                                                                 |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Amenorrhoea, Abnormal uterine bleeding, Recurrent miscarriage, Threatened abortion                                                                                                                                                           |
| Dosing             | IM 65-125mg per week.                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                |
| Contraindications  | Severe hepatic impairment;History of Pruritic Urticarial Papules and Plaques of Pregnancy                                                                                                                                                    |
| Adverse Effects    | Common: Injection site disorder (4.5%), Injection site pain (34.8%), Injection site pruritus (5.8%), Pruritus (7.7%), Swelling at injection site (17.1%), Urticaria (12.3%), Diarrhea (2.3%), Nausea (5.8%) Serious: Thromboembolic disorder |
| Pregnancy          | Unknown                                                                                                                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                                                                                                                      |

